Gregory R. Stuart
University of Victoria
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gregory R. Stuart.
Mutation Research | 2000
Gregory R. Stuart; Erika Thorleifson; Eriko Okochi; Johan G. de Boer; Toshikazu Ushijima; Minako Nagao; Barry W. Glickman
The cII assay provides an alternative choice to the lacI transgene for mutational studies involving Big Blue(R) transgenic mice and rats, or permits the evaluation of mutational responses in both genes. Here, we compare the mutational response of the cII gene from colon of Big Blue(R) F344 rats treated with a dietary mutagen and animal carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), to those previously determined in the lacI transgene from colon of the same group of animals. A cursory inspection of PhIP-induced mutational spectra (MS) in cII and lacI suggests that the two transgenes respond differently to PhIP-induced mutation. However, a more thorough analysis of the MS in the two transgenes, including consideration of the number of mutational target sequences in each gene and nearest neighbor analyses of mutated nucleotides, indicates that PhIP-induced mutational specificity is similar in both genes. The evaluation of PhIP-induced mutational responses in these two transgenes serves as a model for intergenic mutational analyses.
Nutrition and Cancer | 2001
Haiyan Yang; Gregory R. Stuart; Barry W. Glickman; Johan G. de Boer
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a potent mutagen and suspected human carcinogen present in cooked protein-rich food. It preferentially induced colon tumors in male rats and mammary tumors in female rats. In the present study, the in vivo antimutagenic efficacy of two dietary compounds, conjugated linoleic acid (CLA) and 1,2-dithiole-3-thione (DTT), against PhIP was explored using lacI transgenic Big Blue rats. Five- or six-week-old male Big Blue rats were fed a diet containing CLA (0.5%, wt/wt) or DTT (0.005%, wt/wt) starting one week before exposure to 200 ppm PhIP for 61 days. PhIP treatment induced a ~8- to 16-fold increase in the mutation frequency (MF) in the colon. The induced MF was significantly lower in the cecum than in the proximal and distal colon (~52 ×105 vs. 100 ×105, p < 0.008). CLA and DTT significantly reduced the PhIP-induced MF in the distal colon (p < 0.05) by 14% and 24%, respectively. The frequency of -1 frameshift mutations was lower in the distal colon of CLA- or DTT-treated rats. This protective effect was not observed in the cecum or in the proximal colon. In contrast, the PhIP-induced MF in the cecum (specifically, the frequency of -1 frameshifts and GC --- TA transversions) was elevated by 43% after treatment with CLA. In conclusion, CLA and DTT modulate PhIP-induced mutagenesis in a tissue-specific manner, and different modulation pathways are employed by CLA and DTT.
Environmental and Molecular Mutagenesis | 1996
Gregory R. Stuart; Nancy J. Gorelick; Julie L. Andrews; de Boer Jg; Barry W. Glickman
The Big Blue® lacl transgenic rodent assay, which uses the λLIZ/lacl gene as the target for mutation, provides a convenient short‐term assay for the study of mutation in viva [Kohler et al. [1991]: Proc Natl Acad Sci USA 88:7958–7962; Provost et al. (1993): Mutat Res 288:133–149]. However, the interpretation of data from transgenic animal assays is sometimes complicated by mutants that appear as sectored mutant lambda plaques. These mutants can form a significant fraction of the mutant plaques [Hayward et al. (1995): Carcinogenesis 16:2429–2433]. Thus, in order to accurately determine in vivo mutant frequencies and mutational specificities, it is necessary to score sectored plaques and partition them from the rest of the data. In this study, the specificity of mutation in sectored plaques recovered from untreated and UVB‐treated Big Blue® mouse skin was analyzed and compared to mutations recovered from λLIZ/lacl grown on the Escherichia coli host. The mutational spectra of sectored plaques from untreated and UVB‐treated mice were remarkably similar to each other and resembled those recovered from the λLIZ/lacl phage plated directly on E. coli. Both the sectored mutants and those recovered in λLIZ/lacl phage differed from the spectra of spontaneous mutants in E. coli and in Big Blue® mouse skin. While sectored mutants from UVB‐treated mouse skin and λLIZ/lacl mutants were also different from spontaneous mutants recovered from Big Blue® liver, there was little difference between sectored mutants from untreated mouse skin and spontaneous liver mutants (P = 0.07). The mutational spectra of sectored plaques is thus largely consistent with their origin as spontaneous mutations arising in vitro during growth of the λLIZ/lacl shuttle vector DNA on the E. coli host, although the potential contribution from lesions in mouse DNA being expressed ex vivo in the E. coli host cannot be excluded.
Mutation Research | 2001
A.S. Thornton; Yoshimitsu Oda; Gregory R. Stuart; Barry W. Glickman; J.G. de Boer
The compound 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a significant environmental contaminant resulting from such industrial processes as pulp and paper production. TCDD is a suspected human carcinogen and its ability to induce cancer in laboratory rodents is well documented. Its mechanism of tumor initiation, however, is not well understood and in vitro mutagenicity studies have yielded inconsistent results. In this study, Big Blue lacI transgenic rats were used to assess the mutagenicity of TCDD in both male and female animals. After 6 weeks of exposure to 2 microg/kg TCDD neither an increase in mutation frequency nor any change in mutation spectrum was observed in either male or female animals.
Mutation Research | 1996
Mary Mazur-Melnyk; Gregory R. Stuart; Barry W. Glickman
Benzo[a]pyrenediol-epoxide (BPDE), a metabolite of the ubiquitous environmental carcinogen benzo[a]pyrene (B[a]P), has been implicated as a point mutagen. However, as mutational events other than point mutations are also often associated with cancer, we have investigated whether BPDE can induce other classes of mutation. This was done by analyzing mutation at the aprt and hprt loci, both in hemizygous (D422) and heterozygous (D423) Chinese hamster ovary (CHO) cell strains. Southern blotting analysis indicated that BPDE is not an effective producer of either deletions or insertions in the hemizygous environment. The analysis of mutation in the aprt heterozygote was done to investigate the frequency of loss of heterozygosity (LOH) events following BPDE treatment. Using PCR to produce an artificial restriction fragment length polymorphism in the functional aprt allele, BPDE was found to induce LOH in about one-quarter of the mutants recovered. While the precise mechanism of this phenomenon remains obscure, it is likely to have important implications, since similar events involving homologous recombination in somatic cells may have an impact in tumorigenesis.
Genetics | 2000
Gregory R. Stuart; Oda Y; de Boer Jg; Barry W. Glickman
Cancer Research | 2000
Gregory R. Stuart; James Holcroft; Johan G. de Boer; Barry W. Glickman
Mutation Research-genetic Toxicology and Environmental Mutagenesis | 1997
Hideo Okonogi; Gregory R. Stuart; Eriko Okochi; Toshikazu Ushijima; Takashi Sugimura; Barry W. Glickman; Minako Nagao
Genetics | 2000
Gregory R. Stuart; Barry W. Glickman
Carcinogenesis | 2000
Gregory R. Stuart; Yoshimitsu Oda; Johan G. de Boer; Barry W. Glickman